A study comparing efficacy and safety of oral rivaroxaban and subcutaneous low molecular weight heparin maintenance therapy for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress